Innoviva (NASDAQ: INVA) is one of 102 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Innoviva to related businesses based on the strength of its valuation, dividends, profitability, analyst recommendations, earnings, institutional ownership and risk.

Analyst Ratings

This is a summary of current ratings and recommmendations for Innoviva and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innoviva 1 3 1 0 2.00
Innoviva Competitors 864 3784 6745 180 2.54

Innoviva currently has a consensus price target of $13.00, suggesting a potential downside of 0.99%. As a group, “Pharmaceuticals” companies have a potential upside of 24.64%. Given Innoviva’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Innoviva has less favorable growth aspects than its rivals.

Insider & Institutional Ownership

74.4% of Innoviva shares are owned by institutional investors. Comparatively, 45.4% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.6% of Innoviva shares are owned by company insiders. Comparatively, 11.4% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Innoviva has a beta of 2.51, suggesting that its stock price is 151% more volatile than the S&P 500. Comparatively, Innoviva’s rivals have a beta of 36.48, suggesting that their average stock price is 3,548% more volatile than the S&P 500.

Profitability

This table compares Innoviva and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Innoviva 52.91% -33.55% 26.40%
Innoviva Competitors -2,468.15% -71.27% -8.14%

Earnings and Valuation

This table compares Innoviva and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Innoviva $133.57 million $59.53 million 15.09
Innoviva Competitors $8.17 billion $1.09 billion 123.32

Innoviva’s rivals have higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Innoviva rivals beat Innoviva on 9 of the 13 factors compared.

About Innoviva

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Receive News & Stock Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related stocks with our FREE daily email newsletter.